Evanthia Galanis
Alliance Foundation Trials, LLC. · Alliance Foundation Trials · Mayo Clinic in Rochester
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Evanthia Galanis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07149363 · Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung CancerAlliance Foundation Trials, LLC. · recruiting · Small Cell Lung Cancer (SCLC) · principal investigator
- Ph2NCT05798663 · Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCAlliance Foundation Trials, LLC. · active not recruiting · NSCLC · principal investigator
- Ph2NCT04335682 · Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or EnzalutamideAlliance Foundation Trials, LLC. · completed · Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer · principal investigator
- Ph2NCT04062708 · CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerAlliance Foundation Trials, LLC. · active not recruiting · Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer · principal investigator
- Ph2NCT04009109 · Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMAlliance Foundation Trials, LLC. · active not recruiting · Myeloma, Multiple · principal investigator
- Ph1NCT03702725 · Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaAlliance Foundation Trials, LLC. · completed · Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma · principal investigator
- Ph2NCT03478514 · Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaAlliance Foundation Trials, LLC. · active not recruiting · Mantle Cell Lymphoma, B Cell Lymphoma · principal investigator
- Ph3NCT03009981 · A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerAlliance Foundation Trials, LLC. · completed · Prostate Cancer · principal investigator
- Ph3NCT02513394 · PALbociclib CoLlaborative Adjuvant StudyAlliance Foundation Trials, LLC. · active not recruiting · Breast Cancer · principal investigator
- Ph2NCT02364713 · MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal CancerMayo Clinic · terminated · Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma · principal investigator
- Ph1/Ph2NCT02068794 · MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube CancerMayo Clinic · active not recruiting · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma · principal investigator
- Ph1/Ph2NCT01648348 · Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeNational Cancer Institute (NCI) · completed · Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma · principal investigator
- Ph2NCT00892177 · Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma MultiformeAlliance for Clinical Trials in Oncology · completed · Glioblastoma Multiforme · study chair
- Ph1/Ph2NCT00731731 · Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeNational Cancer Institute (NCI) · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph2NCT00651157 · Viral Therapy in Treating Patients With Metastatic MelanomaNational Cancer Institute (NCI) · completed · Recurrent Melanoma, Stage IV Melanoma · principal investigator
- Ph2NCT00641706 · Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeNational Cancer Institute (NCI) · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph2NCT00621686 · Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma MultiformeAlliance for Clinical Trials in Oncology · completed · Brain and Central Nervous System Tumors · study chair
- Ph1NCT00408590 · Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerMayo Clinic · completed · Ovarian Cancer, Primary Peritoneal Cavity Cancer · study chair
- Ph1NCT00390299 · Viral Therapy in Treating Patients With Recurrent Glioblastoma MultiformeMayo Clinic · completed · Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma · principal investigator
- Ph2NCT00238303 · Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeNational Cancer Institute (NCI) · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph1NCT00121745 · Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic CancerEpeius Biotechnologies · terminated · Pancreatic Cancer · principal investigator
- Ph2NCT00098553 · Everolimus in Treating Patients With Stage IV MelanomaAlliance for Clinical Trials in Oncology · completed · Melanoma (Skin) · unknown
- Ph2NCT00005976 · Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent GliomaNational Cancer Institute (NCI) · completed · Brain and Central Nervous System Tumors · study chair
- Ph2NCT00016328 · CCI-779 in Treating Patients With Recurrent Glioblastoma MultiformeNational Cancer Institute (NCI) · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · fiscal years 2023 to 2026 · $2,485,410 awarded in 2026Grant number is on one of their registry trials
- Alliance NCORP Research BaseUG1CA189823 · NCI · ALLIANCE NCTN FOUNDATION · fiscal years 2023 to 2026 · $8,137,751 awarded in 2026Same name and institution; not confirmed by an ID
- Center of Innovation for Brain Tumor TherapeuticsU19CA264362 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2021 to 2025 · $1,203,578 awarded in 2025Same name and institution; not confirmed by an ID
- Novel multipronged Immunovirotherapy Approach for GBM TreatmentR01CA258239 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2021 to 2025 · $334,372 awarded in 2025Same name and institution; not confirmed by an ID
- Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2016 to 2021 · $225,862 awarded in 2021Same name and institution; not confirmed by an ID
- Gene and Virus Therapy ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2014 to 2020 · $45,693 awarded in 2020Grant number is on one of their registry trials
- Optimizing Delivery of Oncolytic Measles Virus Strains with Cell CarriersR01CA200507 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2017 to 2020 · $584,773 awarded in 2020Grant number is on one of their registry trials
- Optimizing Measles Virotherapy in the Treatment of GliomasP50CA108961 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2004 to 2015 · $210,893 awarded in 2015Grant number is on one of their registry trials
- Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomasR01CA154348 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2011 to 2014 · $318,329 awarded in 2014Same name and institution; not confirmed by an ID
- Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian CancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2009 to 2013 · $393,649 awarded in 2013Grant number is on one of their registry trials
- Optimizing Measles Virotherapy in the Treatment of Ovarian CancerR01CA136547 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2009 to 2012 · $507,051 awarded in 2012Grant number is on one of their registry trials
- Measles Virotherapy for Glioblastoma MultiformeR21CA123839 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2006 to 2007 · $224,632 awarded in 2007Same name and institution; not confirmed by an ID
- INTRAPERITONEAL ADMINISTRATION OF A STRAIN OF MEASLES VIRUS IN OVARIAN CAM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · fiscal years 2004 to 2005 · $15,402 awarded in 2005Same name and institution; not confirmed by an ID
- FUSOGENIC MEMBRANE PROTEINS AS THERAPEUTIC TRANSGENESK08CA084388 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2000 to 2004 · $114,588 awarded in 2004Same name and institution; not confirmed by an ID
- Measles Virus Therapy for Ovarian CancerR21CA103276 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2003 to 2004 · $269,366 awarded in 2004Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- North Central Cancer Treatment GroupU10CA025224 · NCI · MAYO CLINIC ROCHESTER · PI JAN C BUCKNER · fiscal years 1985 to 2013
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:12 UTC. The ranking covers the 200 most relevant of 59 PubMed records, and a shared surname and initials can bring in a namesake. All 59 on PubMed
- 1,410 citationsRCR 55.2
- 989 citationsRCR 38.2
- Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.J Clin Oncol · 2005574 citationsRCR 11.8
- Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.J Clin Oncol · 2009303 citationsRCR 6.7
- Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.Cancer Res · 2002289 citationsRCR 5.6
- 254 citationsRCR 5.7
- 202 citationsRCR 4.3
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.Neuro Oncol · 2012171 citationsRCR 4.4
- Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.J Neurosurg · 1998139 citationsRCR 3.8
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.Neuro Oncol · 2015136 citationsRCR 4.2